So what’s star Broad in­ves­ti­ga­tor Feng Zhang up to now?

Ac­cord­ing to an SEC fil­ing from a few days ago, star Broad in­ves­ti­ga­tor Feng Zhang and a group of high-pro­file sci­en­tists and in­vestors have formed a new biotech called Ar­bor Biotech­nolo­gies and raised $12.2 mil­lion of a $15.6 mil­lion of­fer­ing.

Full cred­it: Reuters briefed the news June 1 and the Boston Busi­ness Jour­nal made the con­nec­tion with the sci­en­tist ear­li­er to­day.

Zhang, you will re­mem­ber, pro­vid­ed much of the orig­i­nal in­sight and IP that went in­to the CRISPR/Cas9 tech in use at Ed­i­tas $ED­IT, one of a group of gene edit­ing ri­vals in that has been duk­ing it out to be the first in the clin­ic with a pi­o­neer­ing hu­man study. That ri­val­ry in­cludes an in­tense dis­pute over the patents the Broad ob­tained. Ed­i­tas has al­so gone on to build its patent port­fo­lio and Zhang has been hard at work search­ing for new and bet­ter ways to do gene edit­ing.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.